Insulet ($PODD), creator of the OmniPod tubeless insulin pump, joined forces with Eli Lilly ($LLY) this week to develop a version of the device designed to deliver Lilly's Humulin R U-500 insulin. The highly concentrated form of insulin allows patients with resistant Type 2 diabetes to administer large doses in a reasonable volume, according to Insulet, and if ensuing clinical trials prove its safety and efficacy, the Omnipod would be the first insulin pump specifically for Humulin R U-500. Insulet touts the FDA-approved device as the "world's first tubeless insulin pump." Release